Workpackage

Bioproduction

Workpackage

Bioproduction

Objective : Develop cell production capacity for both research and clinical (GMP) grade cell-based advanced therapy medicinal products (ATMPs) to be used in the IHU clinical trials.

Bioproduction of cell or cell-derived ATMPs for clinical applications is a critical part of innovative clinical trials to treat auto-immune diseases. It relies on two cardinal features:

1) a specific cell product, genetically engineered, or modified with antibodies, mRNA or complex culture conditions, meeting specifications that can address unmet clinical applications,

2) a GMP-compliant production that ensures that the end product meets preset specifications, including a robust potency test, and that is produced in sterile, traceable and reproducible fashion. We will complement our bioproduction capacity with private and academic partnerships, including partners of the IHU.

WP Leader

John De Vos

Professor

6.1.1. Bioproduction for clinical trial to treat sclerodermia using CART CD19 (SCLEROCAR)

6.1.2. Bioproduction for clinical trial to treat rheumatoid arthritis using CAR Treg cells

6.1.3. Bioproduction for clinical trial to treat sclerodermia using CAR MSC

6.1.4. Bioproduction for clinical trial to treat rheumatoid arthritis and lupus using cord-blood derived NK cells armed with specific antibodies constructs

6.1.5. Bioproduction for clinical trial to treat rheumatoid arthritis using iPSC-derived NK cells armed with specific antibodies constructs

6.2. Manufacturing of MSC-EV.

6.3. GMP manufacturing of RNA

Academic and industrial partners

Latest published scientific articles

Generation of non-genetically modified, CAR-like, NK cells
Loïs Coënon, Emilie Rigal, Hortense Courot, Caroline Multrier, Sara Zemiti, Jennifer Lambour, Martine Pugnière, Marion de Toledo, Guillaume Bossis, Guillaume Cartron, Bruno Robert, Pierre Martineau, Bénédicte Fauvel, Jessy Presumey, Martin Villalba
J Immunother Cancer 2024 Jul 18;12(7):e009070. doi: 10.1136/jitc-2024-009070.

A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe
Joaquín Delgadillo, Erja Kerkelä, Allison Waters, Emilie van den Akker, Chantal Lechanteur, Etienne Baudoux, Nicola Gardiner, John De Vos, Joaquim Vives
Cytotherapy 2023 Dec;25(12):1259-1264. doi: 10.1016/j.jcyt.2023.08.001.

 Differentiation of Human Induced Pluripotent Stem Cells from Patients with Severe COPD into Functional Airway Epithelium
Engi Ahmed, Mathieu Fieldes, Chloé Bourguignon, Joffrey Mianné, Aurélie Petit, Myriam Jory, Chantal Cazevieille, Hassan Boukhaddaoui, James P Garnett, Christophe Hirtz, Gladys Massiera, Isabelle Vachier, Said Assou, Arnaud Bourdin, John De Vos
Cells 2022 Aug 5;11(15):2422. doi: 10.3390/cells11152422.

CRISPR/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particle
Joffrey Mianné, Amel Nasri, Chloé Nguyen Van, Chloé Bourguignon, Mathieu Fieldès, Engi Ahmed, Christine Duthoit, Nicolas Martin, Hugues Parrinello, Anaïs Louis, Alexandra Iché, Régis Gayon, Florine Samain, Lucille Lamouroux, Pascale Bouillé, Arnaud Bourdin, Said Assou, John De Vos
BMC Biol. 2022 Jan 7;20(1):8. doi: 10.1186/s12915-021-01214-x.

Groupes de travail

Les autres workpackages

Les autres groupes de travail pour mener à bien ce projet.

Workpackage

Study the contribution of immune cells to autoimmunity

Workpackage

Restoring immune homeostasis through cell therapy and in vivo cell reprogramming

Workpackage

Comprehensive and predictive models to evaluate drug response and safety

Workpackage

Deep Immunophenotyping and new biomarkers for better patient stratification